Enhanced Glucokinase Activator Therapies for Renal Impairment

Improved glucokinase activator treatments for diabetes with renal impairment, addressing limitations in existing therapies through sustained-release formulations, personalized dosing regimens, and renal-protective agents.

The original patent disclosed glucokinase activator treatments for diabetes with renal impairment, but had limitations in dosing frequency, glucose level monitoring, and potential kidney damage. The new inventive concept addresses these limitations by introducing sustained-release formulations, wearable glucose level tracking, and renal-protective agents to enhance treatment efficacy and safety.

The new inventive concept comprises four key aspects: (1) a sustained-release formulation of the glucokinase activator to reduce dosing frequency, (2) a wearable device and computer program for tracking glucose levels and generating personalized dosing regimens, (3) a glucokinase activator composition with a renal-protective agent to minimize kidney damage, and (4) a genetic profiling method to identify subjects likely to benefit from glucokinase activator treatment. These enhancements improve treatment outcomes, reduce side effects, and enhance patient quality of life.

The new claims introduce non-obvious improvements over the original patent, including the use of sustained-release formulations, wearable glucose level tracking, and renal-protective agents. These innovations provide a significant advancement in the field of glucokinase activator therapies for diabetes with renal impairment.

Alternative embodiments may include different sustained-release formulations, varying wearable device designs, or alternative renal-protective agents. Variations may also include combining glucokinase activators with other diabetes treatments or integrating the wearable device with other health monitoring systems.

The enhanced glucokinase activator therapies have significant commercial potential in the diabetes treatment market, particularly for patients with renal impairment. The market is expected to grow as the prevalence of diabetes and kidney disease increases, and the new inventive concept is well-positioned to capture a significant share of this market.